Gregory Vidal, Director of Clinical Research at West Cancer Center & Research Institute, shared a post on LinkedIn:
“I led a great discussion with Dr. Pooja Advani of Mayo Jacksonville and Dr. Tari King of Emory University at ASCO 2026, on how TDXd (an antibody drug conjugate) has impacted how we treat early Her2 positive breast cancer.
You can also read:
Can HER2DX Help Refine Neoadjuvant Treatment in Early HER2-Positive Breast Cancer?
